2328064-33-9
2328064-33-9
Chemical Structure
(rac)-Lomedeucitinib
Synonym(s): (rac)-BMS-986322
- CAS No.: 2328064-33-9
- Formula:C18H17D3N6O4S
- Molecular Weight:419.47
InChIKey: VWIVBQZLVAGLMH-FIBGUPNXSA-N
SMILES: O=C(C1=NN=C(NC(C2CC23CC3)=O)C=C1NC4=NC=CC=C4S(=O)(C)=O)NC([2H])([2H])[2H]
Biological Activity: (rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(rac)-Lomedeucitinib | 98.11% | (rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Drakos A, et al. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents[J]. Pharmaceutics, 2024, 16(1): 111. [Content Brief]
- [2]. Zhang K, et al. Development and therapeutic implications of tyrosine kinase 2 inhibitors[J]. Journal of Medicinal Chemistry, 2023, 66(7): 4378-4416. [Content Brief]
- [3]. Andrew Nicholas Billin, et al. Il-31 modulators for treating fxr-induced pruritis. WO2022266444A1. 2022-06-17
